4 plaques are then further probabilistically filtered by a simple morphometric classifier which measures and 141 tests the object shape elongation, spatial location/distance to tissue border, and its relative signal strength 142 to tissue background autofluorescence in both green and red channels. Thirty-five of one hundred eleven 143 image series were acquired with a lower PMT voltage (below 750 V) initially and were then processed 144 with a higher sensitivity initial classifier.
145
Automated 3D registration was also performed as previously described (Kuan et al., 2015) . Briefly, 146 segmented fluorescence output is a full resolution mask that classifies each 0.35 µm × 0.35 µm pixel 147 as either signal or background. An isotropic 3D summary of each brain is constructed by dividing each 148 image series into 10 µm × 10 µm x 10 µm grid voxels. Total signal is computed for each voxel by 149 summing the number of signal positive pixels in that voxel. Each image stack is registered in a multi-step 150 process using both global affine and local deformable registration to the 3D Allen Mouse Brain Common 151 Coordinate Framework, v3 (CCFv3). Plaque density for each structure in the reference atlas ontology was 152 calculated by summing voxels from the same structure. We also used a standard feature labeling 153 algorithm to obtain plaque counts within each structure. The algorithm labels the connected components 154 of the registered volume in which any two voxels of segmented plaque areas are connected if the voxels 155 are touching or diagonally adjacent. Due to the 100 µm z-sampling interval, our resolution limit for 156 detecting separate plaques in the z axis was 100 µm. 5 sections were stained with primary antibody overnight (6E10, Covance, Princeton, NJ, Lot 193 #B2286581:1000). After three 2-hour washes in PBS + 0.1% Triton X-100, sections were then incubated 194 in secondary antibody overnight (Alexa Fluor goat anti-mouse 568). After three additional 2-hour washes 195 in PBS + 0.1% Triton X-100, sections were counterstained with DAPI (Invitrogen, Carlsbad, CA, Lot 196 #1874814) and coverslipped with Fluoromount G medium (Southern Biotechnology, Birmingham, AL; 197 catalog #J3017-XE67B). All slides were imaged on the VS120 multichannel epifluorescence microscope 198 system (Olympus, Center Valley, PA) with a 10X objective. Selected ROIs were subsequently imaged on 199 the confocal laser scanning system FV3000 (Olympus, Center Valley, PA).
200
Image Quantification. To quantify the fraction of methoxy-X04 labeled plaques detected by the automated 201 segmentation algorithm following STP imaging, we manually counted the number of plaques in 1.4 mm x 202 1.4 mm ROIs in raw STP coronal images and their associated segmentation mask files (n=15 ROIs total, 203 3 ROIs per experiment in 5 experiments). All ROIs were drawn in the isocortex and hippocampus in 12-204 month-old or 18-month-old brains (n=3 APP/PS1, n=1 Tg2576, n=1 hAPP-J20). We also quantified the 205 fraction of antibody-labeled plaque area detected by STP imaging and automated segmentation of 206 methoxy-X04 labeling. We drew ROIs corresponding to major brain divisions on two sections from a 207 single brain for each mouse line, then applied a threshold to the 6E10 antibody labeling using Fiji (Figure   208 4c). The area in the antibody-labeled image and the corresponding segmentation of the STP image were 209 measured for each ROI, and the fraction detected was quantified as area in segmentation of the STP 210 image / area in thresholded IHC image. To quantify the ratio of dense core to diffuse plaques, we drew 211 polygons around the edge of the methoxy-XO4 labeling and the Aβ antibody fluorescence in maximum 212 intensity projections of confocal images (n=6 plaques per brain, 3 cortical and 3 hippocampal) and 213 measured the area inside each polygon using Fiji (Schindelin et al., 2012) . We used sections from one 214 13-month-old APP/PS1 mouse, one 13-month-old hAPP-J20 mouse, and one 19-month-old Tg2576 215 mouse.
216
Statistics. Previous studies have reported that plaque density is not normally distributed (Liu et al., 2017) .
217
We performed the Shapiro-Wilk test for normality on the 13-month-old APP/PS1 group since it was the 218 only group of mouse line and age having at least 30 samples (Razali & Wah, 2011) . The test rejects the 219 normality of the brain-wide plaque density distribution with a p-value of 0.001. Therefore, unless 220 otherwise specified in the text, we used a Kruskal-Wallis one-way ANOVA with a significance level of 0.05 221 and Wilcoxon rank-sum test for post hoc comparisons for all hypothesis testing herein and we report 222 plaque densities as median ± interquartile range (IQR). 
224
We measured the brain-wide distribution of plaque pathology in three AD mouse models that express 225 mutant forms of APP using a high-throughput, high resolution imaging and analysis pipeline (Figure 1a ).
226
First, plaques were labeled in vivo with i.p. injection of methoxy-X04 one day before transcardial perfusion 227 (Klunk et al., 2002) . Methoxy-X04 crosses the blood brain barrier, labeling amyloid brain-wide and 228 producing bright fluorescence that is natively detectable; properties critical for use in our STP pipeline 229 (Amato, Pan, Schwartz, & Ragan, 2016) . Methoxy-X04 primarily fluoresces in the blue channel, but, at 230 least given our acquisition parameters, some signal was also detected in green and red channels. Some
231
of this signal appears to be autofluorescence, as low, but still detectable, plaque signal was also 232 observed in APP+/-mice that did not receive a methoxy-X04 injection as has been previously reported 233 (Diez, Koistinaho, Kahn, Games, & Hökfelt, 2000; Dowson, 1981; Kwan, Duff, Gouras, & Webb, 2009; D 234 R Thal, Ghebremedhin, Haass, & Schultz, 2002; Zipfel et al., 2003, Figure 1e) . To establish a time 235 course for plaque deposition in each transgenic mouse line, methoxy-X04 injections were performed in 236 multiple age groups between 5 and 19 months (Table 1) . Second, following plaque labeling, brains were 237 imaged with serial two-photon tomography (STP) at high x,y resolution (0.35 x 0.35 μm) every 100 μm 238 throughout the entire rostral-caudal extent of the brain in coronal planes (Figure 1b) . Next, each whole 239 brain image series was processed using the informatics pipeline adapted from (Kuan et al., 2015) . This 240 step consists of two parts; signal detection (segmentation) and registration. We developed a custom-built 241 signal detection algorithm to automatically segment the methoxy-X04 labeled plaques in each serial 242 section (Figure 2 , see methods for details). Segmented image stacks were deformably registered to the 243 Allen 3D Common Coordinate Framework v3 (CCFv3) and resampled to 10 µm voxel resolution ("3D grid 6 files"). Finally, we quantified the segmented methoxy-X04 labeling in terms of density and/or plaque 245 number for every region annotated in the Allen CCFv3 reference atlas across the entire brain.
246

Evaluation of automated plaque segmentation 247
The performance of the segmentation algorithm was analyzed in two ways. First, automatic 248 segmentation results were manually scored for overall quality by an expert annotator (see methods for 249 details). Second, we compared the number of methoxy-X04 labeled plaques detected by the automated 250 segmentation algorithm with the number of plaques manually identified on the raw images for a subset of 251 experiments and regions of interest (ROIs). On average, the automated segmentation algorithm produced 252 slightly higher plaque counts compared to manual counts (115+/-33%). This discrepancy is likely due in 253 part to the observation that some brain areas were particularly prone to false positives in the 254 segmentation, most often caused by bright tissue edges. These artifacts were commonly seen in the 255 cerebellum, around the edges of ventricles, particularly the cerebral aqueduct (Figure 2d) , in the rostral 256 cortex, particularly layer 1 of orbital cortex, and in the glomerular layer of the olfactory bulb where 257 lipofuscin deposits could not be distinguished from methoxy-X04-labeled plaques. The segmentation and 258 3D grid files were manually checked for every brain, with particular attention paid to these artifact-prone 259 areas.
260
Since some regions of the brain were prone to segmentation artifacts, confidence in automatically-261 generated quantification of plaque densities is lower for some regions than others. To determine which 262 regions were the most problematic (and therefore had the lowest confidence), we subjected a set of 35 263 STP image series from wild type, non-transgenic APP -/littermates with and without methoxy-X04
264
injections, to the same analysis pipeline as our APP +/brains, except for the segmentation QC, so that we 265 could directly measure the occurrence of artifacts contributing to false positives in our data. Following the 266 application of the plaque segmentation algorithm to these brains, we quantified the percentage of voxels 267 containing false positive signal for structures in the isocortex, hippocampus, midbrain, olfactory areas,
268
and cortical subplate (Figure 2e-i) . To estimate the magnitude of false positive signals across the whole 269 brain, we calculated the relative error per structure by subtracting the mean signal in the control dataset 270 from the mean signal in the full plaque dataset for every structure in annotated in the Allen CCFv3 271 reference atlas (840 structures). The mean false positive signal for every structure is plotted in Figure 2j 272 and included in Appendix 1. Fifty-two percent of structures had an error between -0.1 and 0.1 indicating 273 that less than 0.1% of their signal was affected by false positives. There was a second, smaller peak in 274 the histogram around 0.5% composed of structures that had some false positive signal. Sixteen percent 275 of structures had more than 0.5% difference between their plaque density and their false positive density,
276
and no structure had more than a 0.9% difference (Figure 2j ). Sixteen percent of the 840 structures had 277 small negative values for the difference between signal and false positive percent coverage, indicating 278 higher false positives than true plaque signal. However, it is important to note that the control dataset did We explored several features for quantifying plaque pathology. Most frequently, we report plaque density 288 per structure, defined as the percent of each structure's total volume that contains segmented plaque 289 signal. We also automatically calculated plaque counts based on the segmentation results. To accomplish 290 this, we computationally identified voxels with segmented plaque that were touching and/or diagonally 291 adjacent to each other in the 3D grid images (Figure 3) . Our 100 µm z-sampling interval caused plaques 292 to have an elongated appearance along the anterior-posterior axis (Figure 3c,d) . However, we also 293 identified individual plaques that extended for several millimeters across serial sections, much further 294 than our sampling interval would explain. This was particularly apparent along the midline where many 7 plaques appeared to follow the path of the vasculature. This was more obvious in hAPP-J20 and Tg2576 296 mice (Figure 3e , f) than in APP/PS1 mice (Figure 3d ), but was observed in all three APP mouse lines.
297
Because we could not easily differentiate between these extended length vascular-associated plaques 298 and the non-vascular plaques based on the automated counting results, in most of our subsequent 299 analyses we report plaque density to describe pathological load. However, the number of plaques per 300 cubic mm are reported in Figure 5a and included in Appendix 2, and it should be noted that these values 301 were not corrected for the presence of vascular-associated plaques.
302
Methoxy-X04, a congo red derivative, was reported to label dense-core amyloid but not diffuse plaques 303 (Condello, Schain, & Grutzendler, 2011) . Thus, we wanted to characterize the relative fraction of total 304 plaque detectable with methoxy-X04 compared to labeling sections with an Aβ antibody. We retrieved 305 individual sections from a subset of experiments following methoxy-X04 labeling and STP imaging, and 306 immunostained them with the 6E10 anti-Aβ antibody (Figure 4a,b) . We quantified the area covered by 307 plaque in thresholded, antibody-labeled sections compared with the automated segmentation of the same 308 sections (Figure 4c , e.g., compare red to white masks). In all sections, the overall plaque density in the 309 antibody-labeled sections was higher than the automated segmentation of methoxy-X04 fluorescence, but 310 the densities for the two methods of plaque labeling differed between mouse lines (APP/PS1: 10.4±7.8%
311
IHC, 1.2±0.80% segmentation (13-months); Tg2576: 2.8±2.5% IHC, 0.44±0.37% segmentation (19-312 months); hAPP-J20: 7.2±7.2% IHC, 0.08±0.07% segmentation (13-months)). To more directly measure 313 our detection level, we calculated the fraction of Aβ antibody-labeled area that was detected by automatic 314 segmentation of methoxy-X04 fluorescence in the same section for all ROIs in each image. Surprisingly,
315
we found a significant effect of mouse line on the fraction of antibody-labeled plaque area detected 316 (Figure 4f , p=0.04, one-way ANOVA). In APP/PS1 and Tg2576 mouse lines, the fraction detected by 317 segmentation was similar (0.15±0.10 for APP/PS1, 0.15±0.11 for Tg2576), but a lower proportion of 318 antibody labeled plaques were detected in hAPP-J20 (0.03±0.03, p=0.04 compared to APP/PS1, Tukey's 319 post hoc comparison). This line-specific difference may be due to the significantly lower ratio of dense 320 core to diffuse plaque area that we measured in hAPP-J20 mice compared to the other two lines 321 (APP/PS1: 0.09±0.04, Tg2576: 0.1±0.03, hAPP-J20: 0.03±0.02, p=0.001 one-way ANOVA, Figure 4g ).
322
We did not observe any antibody-labeled plaques in regions without methoxy-X04 labeled plaques, and 323 critically, plaque densities measured by both methods are very highly and significantly correlated for all 324 regions tested in all three mouse lines (r=0.95, Figure 4e ), supporting the use of the methoxy-X04 label in 325 our systematic pipeline approach to describe brain-wide distribution of plaques. Thus, we find that 326 methoxy-X04 does underestimate total, or absolute, plaque density (including diffuse plaques) by ~7-to 327 10-fold for APP/PS1 and Tg2576 mice, and ~30-fold for hAPP-J20 mice. Due to this difference in the 328 fraction of plaques labeled with methoxy-X04, plus known differences in the rate of plaque accumulation 329 in each mouse line (Jankowsky & Zheng, 2017), we focused our analysis on patterns of plaque deposition 330 rather than comparing absolute levels between lines. Where we do compare plaque levels (Section 3.3),
331
it is important to note that these reported values refer only to dense-core, not diffuse, plaques.
332
Comparison of Methoxy-X04-labeled plaque levels between three APP mouse models.
333
We measured methoxy-X04 labeled plaque density and count for each mouse line across multiple ages in 334 the whole brain (Figure 5a,b) . Of the three lines, APP/PS1 mice showed the most aggressive rates of 335 dense-core plaque accumulation, as expected from previous reports (Garcia-Alloza et al., 2006;  336 Jankowsky et al., 2004) . Whole-brain dense core-plaque densities were higher in APP/PS1 mice 337 compared to the other two mouse lines in every age group, and whole brain plaque counts were higher in 338 APP/PS1 mice compared to the other two lines for every age except 5 months. At 5 months-old, plaques 339 were readily observable in APP/PS1 mice. Occasionally, but still quite infrequently, plaques were 340 detected in 5 and 7-month-old hAPP-J20 mice. At 13 months, hAPP-J20 mice had significantly higher 341 plaque density than Tg2576 mice (Figure 5b , p=0.04). Very sporadic plaques were observed in Tg2576 342 mice at 13 months, and they then accumulated more plaques rapidly between 13 and 19 months.
343
We also measured methoxy-X04-labeled plaque densities within each of the twelve major brain divisions,
344
and fiber tracts, annotated in the Allen CCFv3 reference atlas. In Figure 5c ,d, we show plaque density 345 across all age groups for the isocortex (Figure 5c ) and hippocampal formation (Figure 5d) , As seen at 346 the whole brain level, methoxy-X04 labeled dense-core plaque densities in these two major regions were 8 also higher in APP/PS1 mice compared to Tg2576 or hAPP-J20 mice at every age. Tg2576 and hAPP-348 J20 mice did not differ in isocortex plaque density, but hAPP-J20 mice had significantly higher plaque 349 density in the hippocampal formation compared to Tg2576 mice at 9 and 13-months-old (p=0.02, p=0.04, 350 Figure 5d ).
351
Temporal and spatial progression patterns of Methoxy-X04 labeled plaques in three APP
352 mouse models.
353
Plaque densities across all the major brain divisions are shown for all three mouse lines in 13-and 19-354 month-old brains in Figure 5e -g. APP/PS1 mice had the highest plaque density in the isocortex but also 355 had dense plaques in olfactory areas, hippocampal formation, cortical subplate, and cerebellum at both 356 13-and 19-months-old. At 13 months, APP/PS1 mice were also beginning to show some plaque 357 accumulation in the thalamus and striatum although the plaque density in these two structures was not 358 significantly higher than the median for the whole brain at either 13 or 19 months. Tg2576 mice had only 359 very sporadic plaques at 13 months, but by 19 months-old their plaque distribution across major regions 360 looked similar to APP/PS1 mice; densest plaques in isocortex, followed by olfactory regions, hippocampal 361 formation, cortical subplate, and cerebellum. However, even though the plaque distribution was broadly 362 similar, Tg2576 still had much lower plaque densities than APP/PS1 mice (note the different scales for 363 the APP/PS1 mouse line plot compared with Tg2576 and hAPP-J20 in Figures 5e and 5g) . Although
364
there was a significant effect of structure on plaque density in major brain divisions in Tg2576 mice
365
(p=10 -5 at 13 months, p=0.001 at 19 months), no individual brain division had a significantly higher plaque 366 density than the median in post hoc testing. Notably, hAPP-J20 mice had a different brain-wide plaque 367 distribution from the other two lines. Plaque levels in the isocortex and hippocampal formation were 368 significantly higher than the whole brain median at 13 months, and plaque density in the cortical subplate 369 was significantly lower than the median at the same time point (Figure 5e ). By 19 months, hAPP-J20 370 mice still had more plaques in the hippocampal formation than any other brain division and there was a 371 significant effect of structure on plaque density (p=0.02), but none of the plaque densities in individual 372 brain divisions were significantly different from the median at 19-months.
373
To examine the regional distribution of methoxy-X04 labeled plaques at a finer scale, we quantified 374 densities for each of 316 subdivisions of the 12 major brain regions (aka, "summary structures") in the 375 Allen CCFv3. Plaque densities are plotted in Figure 6 for summary structures in the 4 major brain 376 divisions with the most plaque (isocortex, hippocampal formation, olfactory areas, and cortical subplate).
377
Very small summary structures are not shown here (i.e., total volume < 0.5% of its major division), but the 378 plaque densities for all structures in all mouse lines and age groups are reported in Appendix 2.
379
The isocortex is parcellated into 43 regions (or, summary structures) in the Allen CCFv3. We observed 380 widespread distribution of plaques across these regions in APP/PS1 mice at 13 and 19 months ( Figure   381 6a). However, there was still some regional specificity within the cortex for this APP line. Plaque densities 382 in the lateral visual area (VISl) were significantly higher than the median plaque density across the entire 383 isocortex at 13 months (Figure 6a,b) . Prefrontal areas prelimbic (PL), infralimbic (ILA), and medial orbital 384 cortex (ORBm), had lower plaque density compared to the whole isocortex median (Figure 6a ). hAPP-
385
J20 mice showed a very striking and specific regional distribution of plaque in the isocortex at both 13 and 386 19 months, but we only performed statistical testing at 13 months since the isocortex was not identified as 387 significant with post-hoc testing across all major divisions at 19 months. Plaque density in the isocortex of 388 13-month-old hAPP-J20 mice was extremely variable, with 23 summary structures having median plaque 389 densities that were significantly higher or lower than the median for the whole structure (Figure 6a ).
390
Specifically, we identified levels that were 5-13 times higher than the median in three subdivisions of 391 retrosplenial cortex (RSPagl, RSPd, RSPv) at 13 months and 2-4 times higher than the median at 19 392 months, an observation consistent with previous reports (Harris et al, 2010) . Interestingly, plaque density 393 in RSPd and RSPv was significantly lower than the isocortex median for APP/PS1 mice (Figure 6a,b) . In VISa, and VISrl) cortex than in other cortical areas at 19 months (Figure 6a ) but there was no significant 399 effect of structure on plaque density in isocortex for this mouse line at any age.
400
The hippocampal formation (HPF) contains 14 summary structures (Figure 6c) , including the 401 hippocampus itself (CA1, CA3, DG, SUB) as well as associated regions (e.g., entorhinal cortex, ENT).
402
Within the HPF, structure had a significant effect on plaque density for every mouse line/age group 403 combination. In the hippocampus proper, all three lines had higher plaque density in the DG than in CA1,
404
CA2, or CA3 (Figure 6c,d) . APP/PS1 and Tg2576 mice also had high plaque density in lateral and 405 medial entorhinal cortex (ENTl and ENTm). hAPP-J20 mice had plaques in ENTm but plaques in ENTl 406 were rarely observed. All three mouse lines had relatively heavy plaque accumulation in the subiculum 407 (SUB) and prosubiculum (ProS), but the Tg2576 mouse line had a strong preferential accumulation of 408 plaques specifically in the dorsal subiculum (Figure 6d , white arrow in Figure 1) . Notably, every single 409 individual Tg2576 mouse that we imaged had plaques in the dorsal subiculum, even at 9 months-old.
410
Two other brain divisions with differences in plaque density between mouse lines were the olfactory areas 411 which had dense plaques in many regions for APP/PS1 and Tg2576 mice, but virtually no plaques in 412 hAPP-J20 mice (Figure 1, Figure 6e ,f) and the cortical subplate which contains several amygdalar 413 structures, where plaques were similarly high in APP/PS1 and Tg2576 but low or absent in hAPP-J20 414 mice (Figure 6g,h) . Importantly, we also did not observe Aβ antibody-labeled plaques in olfactory regions 415 or the amygdala in hAPP-J20 mice. Also of note, both APP/PS1 and Tg2576 mice had plaques in the 416 cerebellum, whereas we did not identify any in hAPP-J20 mice (Figure 7) . APP/PS1 mice developed 417 cerebellar plaques as early as 4 months-old, but plaques were not observed in the cerebellum of Tg2576 418 mice until 19 months-old, and then many were associated with vasculature.
419
We also explored the relationship between regional plaque distribution patterns in the isocortex with the 420 structural connectivity-based isocortical modules found from a network analysis of modeled connectivity 
443
To assist in visualizing the whole brain, 3D, regional distribution patterns of methoxy-X04 labeled plaques 444 for the different ages and mouse lines, we created 3D heatmaps (Figure 9, Figure 10 ). These maps are 445 based on the Allen CCFv3 with each annotated brain structure colored by plaque density. 
451
One spatial feature of amyloid deposition that is easily visualized using the plaque heatmaps is the 452 distribution of plaques by layer in the isocortex. The high density of plaques in layer 5 for APP/PS1 mice 453 and layer 1 for Tg2576 mice are prominent features in the 3D maps (i.e. compare Figure 9b with Figure   454 9d). To quantify differences in plaque density across cortical layers, we calculated the plaque density per 455 layer across all isocortical structures and compared it to the plaque density that would be expected with 456 even plaque distribution based on the relative volume of each layer in the Allen CCFv3. The relative 457 plaque density in each layer for the three mouse lines is plotted in Figure 11 . Plaque density in APP/PS1 458 mice was more uniform across layers than the other two lines, but was higher in layer 5 (p<0.0001 than in 459 layers 4, 6a, and 6b; p=0.03 vs. layer 1; 2-way ANOVA with Sidak's multiple comparisons test) ( Figure   460 11a,b). There appeared to be some regions such as VISrl where plaques were as dense in layer 2/3 as in 461 layer 5 (Figure 9b, Figure 10b) , and indeed the density in layer 5 was not different from layer 2/3 (p=0.8,
462
2-way ANOVA with Sidak's multiple comparisons test). In the retrosplenial cortex of hAPP-J20 mice,
463
plaques density was highest in layer 5 (Figure 9c, Figure 10c ), but in other cortical regions, hAPP-J20 464 and Tg2576 mice both had the highest plaque density in layer 1 (Figure 11c-f, Figure 9c,d ; Figure   465 10c,d). Across all regions, both Tg2576 and hAPP-J20 mice had higher plaque density in layer 1 than in 466 any other layer (p<0.0001, 2-way ANOVA with Sidak's multiple comparisons test). The strong preference 467 for layer 1 plaques in Tg2576 and hAPP-J20 mice appeared to come partly from the surface vasculature 468 which had heavy methoxy-X04 labeling in Tg2576 mice at all ages and 19-month-old hAPP-J20 mice 469 (Figure 4) . In Tg2576 mice, there was no difference in the relative plaque density between layer 2/3 and 470 layer 5, but hAPP-J20 mice had significantly lower plaque density in layer 5 than in layer 2/3 across the 471 whole cortex (p=0.007, two-way ANOVA with Sidak's multiple comparisons).
472
In summary, we quantified patterns of plaque deposition across brain regions at the major division and 473 summary structure level for three APP transgenic mouse lines. We found line-specific differences in 474 plaque density for different brain divisions and for structures within major brain divisions. The pattern of 475 plaque deposition in the isocortex differed between mouse lines at both the regional and layer levels. Figure 12a ), the closest 485 mouse homolog from the Allen CCFv3 reference atlas is listed in the second column. In cases where 486 there was more than one mouse structure that could correspond to the human brain region listed, we 487 used the median plaque density across all the corresponding structures. We calculated the median 488 plaque density per structure across ages for each of the three APP mouse lines and, for APP/PS1 and 489 hAPP-J20 mouse lines, we subtracted the median false positive value for each structure in control mice of 490 the same line. We applied a color map spanning from the 10 th to 90 th percentile of plaque densities for all 491 annotated structures (840) for each group to create a table similar to the one in (Thal, Rüb, et al., 2002) 492 (Figure 12a) . The temporal and regional pattern of plaque deposition for APP/PS1 and Tg2576 mice was 
494
plaques accumulated in the cerebellum (CBX) very early for APP/PS1 mice and were also seen in 495 Tg2576 mice, but plaques were not regularly seen in the cerebellum until the last phase of Aβ deposition,
496
Phase 5, in human brain tissue. Plaque density was high in central gray for all three mouse lines and in 497 the substantia nigra for APP/PS1 and hAPP-J20 mouse lines, but these were both regions in which we 498 observed false positive signal in our automated segmentation, so these values may overestimate the true 499 plaque signal even though we subtracted the control data values. In the top portion of the chart in Figure   500 12a, the plaque distribution in APP/PS1 mice and Tg2576 mice follows a similar step-wise pattern to that 501 11 described in autopsy tissue for Phase 1, Phase 2, and the beginning of Phase 3. The thalamus, 502 hypothalamus, and striatum were key regions that defined Phase 3 for human brains. While APP/PS1 503 mice began to accumulate plaques in the thalamus and striatum at 13 months, at 19-months-old they did 504 not have plaques in the hypothalamus and still had low plaque density in the basal forebrain and 505 brainstem nuclei. This implies that even after aging for 1.5 years, APP/PS1 mice, which had the most 506 aggressive plaque deposition of the three tested, had only partially entered Phase 3. Tg2576 mice had 507 low but measurable plaque density in the thalamus, hypothalamus, and striatum, but we did not observe 508 plaques in these regions so these values were likely false positives.
509
Counting the number of cases in which plaques were observed in all regions from the table would be 510 difficult to perform computationally with our data because of the need to choose a threshold for calling a 511 region "positive" for the presence of plaques. We instead made the assumption that plaque density and 512 percent prevalence are related, and compared the plaque density values from our quantification with the 513 percent prevalence values reported in (Thal, Rüb, et al., 2002) . 
529
We adapted the imaging, automated detection, and registration pipelines previously used for brain-wide 
532
combined with the 3D registration of whole brain image series to the Allen CCF volumetric reference atlas 533 allow us to systematically quantify brain-wide distribution of dense-core plaque pathology at high 534 resolution for a large sample size. The processing of non-transgenic APP -/littermates with the same 535 pipeline facilitated interpretation of results by providing a confidence metric for the automated brain-wide 536 plaque densities reported here. We found that plaque deposition patterns were heterogeneous across 537 structures in all three transgenic mouse lines examined, pointing to the need for robust whole brain 538 characterization to optimize the usage of existing and novel mouse models.
539
Comparing estimates of plaque density across different studies and brain regions is challenging, as it 540 requires considering the labeling method, staining conditions, and imaging conditions used in each study 541 in addition to animal age and transgenic line. Our pipeline approach provided consistency in labeling 542 method and imaging conditions, and our use of automatic segmentation ensured consistent detection of 543 plaque density across many images and samples, allowing us to quantitatively compare plaque density 544 across the whole brain with unprecedented anatomical specificity. However, quantitatively comparing 545 results obtained with different methods of plaque labeling is still an important challenge. We found that 546 methoxy-X04 labeling is inconsistent between mouse lines and that a lower fraction of total plaque area 547 was detected with methoxy-X04 in hAPP-J20 mice compared with APP/PS1 and Tg2576 mouse lines.
548
We measured the magnitude of this difference by comparing automatically-detected methoxy-X04 549 plaques with antibody labeled plaques in the same sections, but it is important to note that our automatic 550 segmentation is based on single confocal section images while the same sections were imaged with a 551 widefield microscope after antibody labeling. However, the ratio between the two labeling methods would 552 not be expected to differ between mouse lines. Importantly, the fraction of individual plaque area covered 12 by methoxy-X04 vs. Aβ antibody measured from confocal sections is similar to the ratio between 554 methoxy-X04 and antibody labeled areas measured in large ROIs (Figure 4f,g) , indicating that the 555 difference in detection likely reflects a biological difference in the composition of plaques for the different 556 mouse lines. To our knowledge, this difference in the ratio of dense-core/diffuse plaques in hAPP-J20 557 mice compared with other APP models has not been previously reported. It will be important to confirm 558 this result using other methods of labeling dense-core and diffuse plaques. Critically, although our 559 experiments underestimate total plaque density, they do represent brain-wide plaque location more 560 precisely than any other study to date in mouse models of AD.
561
Despite the challenges in directly comparing results between labs, we did compare our quantified plaque 
572
month-old age group: cortex median = 0.96 (IQR 0.67-1.8) vs. ~0.13-0.22%). We also report lower 573 densities (0.2% (7 mo), 0.5% (9 mo) vs. ~2% (7-8.5 mo)) than a group using light sheet microscopy to 574 image methoxy-X04-labeled plaques in cleared APP/PS1 mouse brains (Jährling et al., 2015) . The
575
plaque density we measured in 9-month-old hAPP-J20 hippocampus is nearly identical to a recent report 576 using Thioflavin S staining (0.03%, Zhang et al., 2017) . Overall, it seems that the densities we measured 577 are within reported range of previous studies, albeit on the lower end of ranges.
578
Previous studies have reported plaque density in the cortex and hippocampus for different AD mouse 579 models across ages, but generally regional distribution of plaque burden is not resolved beyond these ) are higher than ours by a factor of 585 ~10, which could potentially reflect the higher axial resolution of light sheet microscopy (2.5 µm vs. our 586 100 µm sectioning interval), but may also be caused by our automated detection algorithm merging 587 individual plaques (see Figure 4) . Liebmann et al. did not report plaque densities for all structures across 588 the brain, but the twelve structures with highest plaque burden in APP/PS1 mice in their study generally 589 agreed with our findings. In the isocortex, they found the highest plaque load in layers 2/3 and 5 of 590 primary motor cortex (MOp), layers 2/3 and 5 of barrel cortex (SSp-bfd), supplementary somatosensory 591 cortex (SSs), and dorsal auditory cortex (AUDd). While none of these structures had significantly higher 592 density compared to the median for the isocortex in our data, all regions were in the top 5% of densities 593 for both our 13-month-old and 19-month-old mice. Our results were similarly in agreement with the 594 structures in the hippocampal formation found to have high plaque load (i.e., subiculum, lateral entorhinal 595 cortex, CA1, and the molecular layer of the dentate gyrus, Figure 6 ). 
603
we collected image data using the STP imaging system that was also used to construct the Allen CCFv3, 604 so the variability in our 3D registration to this reference atlas was as low as is technically possible. Our 605 sample size is also very high for some groups, increasing confidence in our results. We put a great deal 13 of effort into developing and validating our custom segmentation algorithm as described in the results, 607 although we did not similarly optimize our plaque counting algorithm, which could potentially be improved 608 with future iteration. Finally, we labeled plaques with methoxy-X04 in vivo, rather than post-hoc, so 609 penetration of the plaque label into the tissue was not a concern. Tissue clearing, however, has the 610 distinct advantage of being amenable to more types of labels, and continues to be further optimized to 611 best combine antibody labeling and high resolution whole brain imaging methods (like STP and light 612 sheet microscopy). It will be useful to compare whole brain quantification of Aβ antibody-labeled plaque 613 density with the methoxy-X04 density reported here, particularly for the hAPP-J20 line since its fraction of 614 dense core plaque labeling is lower than the other APP lines.
615
The advent of PiB-PET imaging as a biomarker in AD has been a major breakthrough for the field. Not 616 only does it allow non-invasive estimation of whole-brain plaque density and deposition patterns in 617 humans, but patients can also be diagnosed with probable AD much earlier in the disease process and 618 clinical trials can be more closely controlled based on biomarker measurements (Counts, Ikonomovic, 
629
For many years, regional distribution patterns have been studied in relationship to tau pathology and its moPrP 6 (4/2) 13 (9/4) 6 (3/3) 39 (36/3) 9 (7/2) hAPP-J20 (APP +/-) PDGF-β 4 (2/2) 3 (2/1) 5 (2/3) 11 (6/5) 3 (0/3) Tg2576 (APP +/-) haPrP 3 (0/3) 5 (0/5) 4 (0/4) Controls APP/PS1 (APP -/-) 2 (2/0) 11 (7/4) 2 (0/2) hAPP-J20 (APP -/-) 2 (1/1) 17 (9/8) 1 (0/1)
930
Transgenic mouse lines used in this study and the number of experimental animals in each group.
931
Numbers in parentheses indicate the number of males and females in each mouse line/age group 932 combination. The promoter used to drive APP expression for each transgenic line is indicated in the table.
933
Control mice were APP -/littermates of experimental mice. f.
934
Human region from Thal et al. 2002
Allen CCFv3 region age -> 5 7 9 13 19 9 13 19 5 7 9 13 19 Phase 5 5 7 9 13 19 9 13 19 5 7 9 13 19
Phase 1 
